Vessi Medical, a Misgav, Israel-based urology medical device company, raised $16.5M in Series A funding.
Backers included ALIVE- Israel HealthTech Fund, and Agriline, which joined The Trendlines Group.
The company intends to use the funds to support expansion of its capabilities, clinical studies in Israel and the U.S., and regulatory clearance.
Led by Founder and CEO Eyal Kochavi, Vessi Medical is an urology medical device company that has developed an IP-protected cryospray system, purposely designed for hollow and humid organs, a novel approach for the treatment of non muscle invasive bladder cancer (NMIBC). Its minimally invasive solution for NMIBC provides a new therapeutic alternative to Transurethral Resection of Bladder Tumor (“TURBT”), the invasive surgical first-line therapy. The technology has been used in a first in human study.
Commenting on the news, Eyal Kochavi said: “We are thrilled to announce the closing of this round, especially during this challenging time. The participation of a global strategic investor in this round is a huge show of confidence in Vessi’s achievements and potential. The financing led by ALIVE will support expanding Vessi’s R&D capabilities, clinical studies in Israel and the U.S., and regulatory clearance, enabling us to achieve our goal of bringing Vessi’s treatment for NMIBC to patients and physicians to reduce side effects, improve patient outcomes, and lower health care costs.”
FinSMEs
15/02/2024